Lazard Asset Management
TLX

Lazard Asset Management’s Telix Pharmaceuticals TLX Stock Holding History

Lazard Asset Management’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.28M Sell
284,207
-5,710
-2% -$58.1K 0.01% 765
2026
Q1 		$2.77M Buy
289,917
+39,400
+16% +$300K ﹤0.01% 761
2025
Q4 		$1.88M Buy
250,517
+135,893
+119% +$1.31M ﹤0.01% 894
2025
Q3 		$1.1M Buy
+114,624
New +$1.4M ﹤0.01% 1110

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $358M AUM 26.37% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $15.3B AUM 25.33% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
RBI
Raiffeisen Bank International Vienna, Austria $8.53B AUM 46.94% 1-Year Est. Return

Lazard Asset Management's TLX Position: Q2 2026 in Review

Lazard Asset Management reduced its Telix Pharmaceuticals (TLX) stake by 2% in Q2 2026, selling an estimated $58.1K and leaving 284,207 shares worth $3.28M. The position accounts for 0.01% of the portfolio, ranked #765.

Lazard Asset Management first reported a position in TLX in Q3 2025 and has held it in 4 quarters since. 61 funds tracked by Wall St. Rank hold TLX as of Q2 2026.

  • Lazard Asset Management held 284,207 shares of Telix Pharmaceuticals worth $3.28M as of Q2 2026.
  • Lazard Asset Management sold 5,710 Telix Pharmaceuticals shares in Q2 2026, an estimated $58.1K.
  • Telix Pharmaceuticals made up 0.01% of Lazard Asset Management's portfolio in Q2 2026, its #765 holding.
  • Lazard Asset Management first reported a position in Telix Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 61 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.